AZN
ASTRAZENECA PLC
NYSE: AZN · Cambridge · Healthcare
$183.43+1.88 (+1.04%)Closed
Market Cap—
Cash—most recent
Runway—
P/E (TTM)—
52-Wk Range$135.08 – $208.62
Avg Volume2.5M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$183.43+18.7%
Pipeline
Drug candidates sponsored by ASTRAZENECA · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | Esomeprazole | Gastroesophageal Reflux Disease (GERD) | Completed | 2003-08past | 1 | |
| Phase 4 | Candesartan Cilexetil | Non-diabetic Nephropathy With Hypertension | Completed | 2009-08past | 1 | |
| Phase 4 | Quetiapine XR (Seroquel XR) | Schizophrenia | Completed | 2010-03past | 1 | |
| Phase 4 | EGFR Mutation Test | Non-small Cell Lung Cancer | Completed | 2010-04past | 1 | |
| Phase 4 | Fulvestrant | Locally Advanced or+1 more | Completed | 2016-05-06past | 1 | |
| Phase 4 | Ticagrelor | Stable Coronary Artery Disease+2 more | Completed | 2019-12-13past | 2 | |
| Phase 4 | Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily. | COPD | Withdrawn | 2025-12-31past | 1 | |
| Phase 3 | budesonide/formoterol Turbuhaler | Asthma | Completed | 2006-10past | 1 | |
| Phase 3 | Quetiapine | Psychotic Disorders+2 more | Terminated | 2007-08past | 1 | |
| Phase 3 | ABT-335 and rosuvastatin calcium | Hypercholesterolemia+1 more | Completed | 2008-02past | 1 | |
| Phase 3 | Quetiapine fumarate XR | Acute Bipolar Depression | Completed | 2011-03past | 1 | |
| Phase 3 | TC-5214 | Major Depressive Disorder+2 more | Completed | 2012-01past | 2 | |
| Phase 3 | budesonide/formoterol 'as needed' + budesonide placebo bid | Asthma | Completed | 2017-08-02past | 1 | |
| Phase 3 | AZD9291 | Locally Advanced or Metastatic EGFR T790M+ NSCLC | Completed | 2017-08-21past | 1 | |
| Phase 3 | Roxadustat | Anemia | Completed | 2018-09-26past | 1 | |
| Phase 3 | Sodium Zirconium Cyclosilicate 5g | Hyperkalemia | Completed | 2022-09-15past | 1 | |
| Phase 3 | Trastuzumab Deruxtecan | Breast Cancer | Active, not recruiting | 2024-02-08past | 1 | |
| Phase 3 | Dapagliflozin | Type 2 Diabetes+5 more | Completed | 2024-04-15past | 6 | |
| Phase 3 | BFF MDI 160/9.6 μg BID (320/19.2μg/day) | Asthma | Completed | 2024-11-19past | 1 | |
| Phase 3 | Anifrolumab | Active Systemic Lupus Erythematosus | Completed | 2025-04-07past | 1 | |
| Phase 3 | AZD0780 | Heterozygous Familial Hypercholesterolaemia | Active, not recruiting | 2027-01-04 | 1 | |
| Phase 3 | Volrustomig | Unresectable Pleural Mesothelioma+1 more | Recruiting | 2027-07-30 | 2 | |
| Phase 3 | Durvalumab | Non-Small Cell Lung Cancer+8 more | Recruiting | 2028-10-31 | 3 | |
| Phase 3 | Dato-DXd | Breast Cancer | Active, not recruiting | 2028-11-20 | 1 | |
| Phase 3 | Benralizumab | Asthma | Recruiting | 2030-05-05 | 2 | |
| Phase 2 | AZD3355 | Reflux Episodes | Completed | 2008-02past | 1 | |
| Phase 2 | AZD6244 | Melanoma+1 more | Completed | 2008-04past | 2 | |
| Phase 2 | AZD4818 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2008-06past | 1 | |
| Phase 2 | AZD0328 | Schizophrenia | Terminated | 2008-11past | 1 | |
| Phase 2 | Roflumilast cream | Plaque Psoriasis | Withdrawn | 2009-06past | 1 | |
| Phase 2 | Formoterol Fumarate in the Pressair DPI, Low Dose | Asthma | Completed | 2013-02past | 1 | |
| Phase 2 | MEDI8968 | Hidradenitis Suppurativa | Terminated | 2014-10past | 1 | |
| Phase 2 | AZD1775 | Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer | Terminated | 2015-06past | 1 | |
| Phase 2 | Brazikumab IV Infusion | Crohn's Disease | Terminated | 2017-07-28past | 1 | |
| Phase 2 | AZD5718 | Chronic Kidney Disease | Terminated | 2022-09-06past | 1 | |
| Phase 2 | osimertinib | Lung Cancer | Terminated | 2023-03-09past | 1 | |
| Phase 1 | AZD8853 | Urinary Bladder Neoplasms+2 more | Terminated | 2023-06-06past | 1 | |
| Phase 2 | Brazikumab | Ulcerative Colitis+1 more | Terminated | 2023-10-23past | 1 | |
| Phase 2 | AZD0901 | Gastroesophageal Adenocarcinoma | Recruiting | 2027-01-28 | 1 | |
| Phase 1 | AZD4956 | Solid Tumours | Recruiting | 2030-03-29 | 1 | |
| Phase 2 | Anastrozole | Breast Cancer | Completed | — | 1 | |
| Phase 1 | AZD5438 | Neoplasms | Completed | 2005-12past | 1 | |
| Phase 1 | AZD1305 | Healthy | Completed | 2008-07past | 1 | |
| Phase 1 | AZD6280 | Anxiety | Completed | 2008-09past | 1 | |
| Phase 1 | ABT-143 | Healthy | Completed | 2008-11past | 1 | |
| Phase 1 | AZD1656 | Type 1 Diabetes | Completed | 2009-03past | 1 | |
| Phase 1 | AZD9819 | Healthy Volunteers+2 more | Completed | 2011-01past | 1 | |
| Phase 1 | AZD3514 | Prostate Cancer | Completed | 2013-03past | 1 | |
| Phase 1 | AZD9977 immediate release (IR) oral suspension | Pharmacokinetics+3 more | Withdrawn | 2016-01past | 1 | |
| Phase 1 | Placebo | Pulmonary/Respiratory Diseases | Completed | 2018-04-12past | 1 | |
| Phase 1 | Part A: AZD8186 monotherapy | Advanced Castrate-resistant Prostate Cancer CRPC+2 more | Completed | 2019-03-31past | 1 | |
| Phase 1 | Tezepelumab | Asthma | Completed | 2019-12-30past | 1 | |
| Phase 1 | nirsevimab | Evaluate PK Profile | Completed | 2021-11-18past | 1 | |
| Phase 1 | Adavosertib | Advanced Solid Tumours | Terminated | 2022-06-01past | 1 | |
| Phase 1 | AZD0466 | Haematological Malignancies | Terminated | 2023-08-08past | 1 | |
| Phase 1 | AZD5055 | Healthy Participants | Completed | 2023-12-04past | 1 | |
| Phase 1 | Mitiperstat | Hepatic Impairment | Completed | 2024-11-21past | 1 | |
| Phase 1 | AZD6793 | Type 2 Diabetes Mellitus | Suspended | 2026-06-18 | 1 | |
| Phase 1 | Surovatamig | Rheumatoid Arthritis+1 more | Recruiting | 2028-06-27 | 1 | |
| Phase 1 | AZD3480 | Alzheimer's Disease | Completed | — | 1 | |
| Phase 1 | Esomeprazole/ASA Fixed Combination | Peptic Ulcer Disease | Terminated | — | 1 | |
| Early Phase 1 | Rosuvastatin | Atherosclerosis+1 more | Completed | — | 1 | |
| N/A | Unnamed | Chronic Obstructive Pulmonary Disease | Completed | 2007-09past | 1 | |
| N/A | Candesartan Cilexeotil 16mg | Primary Hypertension | Completed | 2008-02past | 1 | |
| N/A | Unnamed | Osteoarthritis of the Knee | Completed | 2012-06past | 1 | |
| N/A | Unnamed | COPD | Completed | 2013-04past | 1 | |
| N/A | Unnamed | 2 Years PSA Recurrence Rate | Completed | 2014-08past | 1 | |
| N/A | Unnamed | Type 2 Diabetes | Completed | 2016-12-26past | 1 | |
| N/A | Unnamed | Patients With Asthma-COPD Overlap Syndrome (ACOS) | Completed | 2017-04-28past | 1 | |
| N/A | Unnamed | Ovarian, Peritoneal, Fallopian Tube Cancer, BRCAm+ in Russia | Completed | 2018-05-31past | 1 | |
| N/A | Unnamed | Type 2 Diabetes | Completed | 2021-03-01past | 1 | |
| N/A | Aclidinium bromide | Pulmonary Disease, Chronic Obstructive | Completed | 2022-06-30past | 1 | |
| N/A | Unnamed | Severe Asthma | Completed | 2022-11-03past | 1 | |
| N/A | Unnamed | Covid-19 Infection | Completed | 2023-01-27past | 1 | |
| N/A | Unnamed | Carcinoma, Non-Small-Cell Lung | Completed | 2024-02-29past | 1 | |
| N/A | BGF | Pulmonary Disease, Chronic Obstructive | Completed | 2024-10-18past | 1 | |
| N/A | Unnamed | Pancreatic Neoplasms | Completed | 2025-02-06past | 1 | |
| N/A | Cohort | Severe Eosinophilic Asthma | Completed | 2025-04-13past | 1 | |
| N/A | budesonide / glycopyrronium / formoterol | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2025-11-17past | 1 | |
| N/A | Unnamed | Respiratory (Chronic Obstructive Pulmonary Disease) | Recruiting | 2026-09-30 | 1 | |
| N/A | Unnamed | Hyperkalemia | Recruiting | 2026-09-30 | 1 | |
| N/A | Unnamed | Breast Cancer | Recruiting | 2028-01-31 | 1 | |
| N/A | Unnamed | Rare Diseases+1 more | Recruiting | 2029-12-31 | 1 | |
| N/A | Unnamed | Transthyretin Amyloidosis | Recruiting | 2035-12-30 | 1 | |
| N/A | Unnamed | Gastroesophageal Reflux | Completed | — | 1 | |
| N/A | Unnamed | Major Depressive Disorder | Completed | — | 1 | |
| N/A | Unnamed | Hypertension | Completed | — | 1 | |
| N/A | Unnamed | Asthma | Completed | — | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for AZN. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.